@entity4944 increases activity but not exploration in XXXX and @entity19 .

@entity1 @entity162 @entity2254 @entity5733 @entity146 @entity935 @entity19 @entity2915 @entity4944 @entity1063
RATIONALE: Cross-species quantification of physiological behavior enables a better understanding of the biological systems underlying @entity146 such as @entity162 ( @entity162 ). Cardinal symptoms of @entity162 include increased motor activity and goal-directed behavior, thought to be related to increased @entity5733 activity, potentially selective to @entity935 homeostatic dysregulation. OBJECTIVES: The objective of this study was to test whether acute administration of @entity4944 , a @entity1063 / @entity935 transporter inhibitor and @entity935 releaser, would replicate the profile of activity and exploration observed in both @entity1 with @entity162 and @entity19 models of @entity162 . METHODS: Healthy volunteers with no @entity146 history were randomized to a one-time dose of placebo (n   =   25), 10  mg @entity2254 (n   =   18), or 20  mg @entity4944 (n   =   23). Eighty @entity19 were administered one of four doses of @entity2254 or vehicle. @entity1 and @entity19 were tested in the behavioral pattern monitor (BPM), which quantifies motor activity, exploratory behavior, and spatial patterns of behavior. RESULTS: In @entity1 , the 20-mg dose of @entity4944 increased motor activity as measured by acceleration without marked effects on exploration or spatial patterns of activity. In @entity19 , @entity4944 increased activity, decreased specific exploration, and caused straighter, one-dimensional movements in a dose-dependent manner. CONCLUSIONS: Consistent with @entity19 , @entity4944 increased motoric activity in @entity1 without increasing exploration. Given that @entity162 @entity1 exhibit heightened exploration, these data further emphasize the limitation of @entity4944 -induced @entity2915 as a suitable model for @entity162 . Further, these studies highlight the utility of cross-species physiological paradigms in validating biological mechanisms of @entity146 .
